Skip to main content

Sera Prognostics, Inc. (SERA)

NASDAQ: SERA · IEX Real-Time Price · USD
10.41 -0.34 (-3.16%)
Oct 21, 2021 10:14 AM EDT - Market open
Market Cap317.60M
Revenue (ttm)30,000
Net Income (ttm)-21.51M
Shares Out30.51M
EPS (ttm)-0.71
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,761
Open10.73
Previous Close10.75
Day's Range10.25 - 10.73
52-Week Range7.61 - 15.50
Betan/a
AnalystsStrong Buy
Price Target18.00 (+72.9%)
Est. Earnings DateNov 15, 2021

About SERA

Sera Prognostics is a women’s health diagnostic company utilizing our proprietary proteomics and bioinformatics platform to discover, develop and commercialize clinically meaningful and economically impactful biomarker tests, with an initial focus on improving pregnancy outcomes. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to dramatically reduce healthcare costs. Our first commercial product, the PreTRM test, is ...

IndustryDiagnostics & Research
IPO DateJul 15, 2021
CEO​ Gregory C. Critchfield, M.D., M.S.
Employees71
Stock ExchangeNASDAQ
Ticker SymbolSERA
Full Company Profile

Financial Performance

In 2020, SERA's revenue was $25,000, a decrease of -30.56% compared to the previous year's $36,000. Losses were -$19.85 million, 20.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for SERA stock is "Strong Buy." The 12-month stock price forecast is 18.00, which is an increase of 72.91% from the latest price.

Price Target
$18.00
(72.91% upside)
Analyst Consensus: Strong Buy

News

Sera Prognostics Appoints Dr. Paul Kearney as Chief Data Officer

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

3 weeks ago - GlobeNewsWire

Sera Prognostics to be Added to Russell 2000 Index

SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...

1 month ago - GlobeNewsWire

Sera Prognostics Appoints Dr. Michael R. Foley as Chief Medical Officer

SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...

1 month ago - GlobeNewsWire

Sera Prognostics to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit

SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy bioma...

1 month ago - GlobeNewsWire

Sera Prognostics Reports Second Quarter 2021 Financial Results

SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomar...

1 month ago - GlobeNewsWire

Sera Prognostics Announces Pricing of Initial Public Offering

SALT LAKE CITY, July 14, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker in...

3 months ago - GlobeNewsWire

Sera Prognostics IPO Registration Document (S-1)

Sera Prognostics, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC

Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk...

The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

5 months ago - GlobeNewswire